Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its quarterly earnings data on Monday. The company reported ($0.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.42) by $0.03, Analyst Ratings Network reports.

On a related note, analysts at Robert W. Baird initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 15th. They set an “outperform” rating and a $64.00 price target on the stock. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $74.00.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 49.55 on Monday. Ultragenyx Pharmaceutical has a 1-year low of $32.02 and a 1-year high of $69.774. The stock’s 50-day moving average is $44.55 and its 200-day moving average is $45.04. The company’s market cap is $1.488 billion.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.